CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 150 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2014. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $167,000 | +5.7% | 58,500 | -5.0% | 0.01% | +16.7% |
| Q2 2017 | $158,000 | -27.5% | 61,550 | -5.2% | 0.01% | -25.0% |
| Q1 2017 | $218,000 | +17.8% | 64,930 | +18.2% | 0.02% | +14.3% |
| Q4 2016 | $185,000 | +1.6% | 54,930 | -0.6% | 0.01% | 0.0% |
| Q3 2016 | $182,000 | -27.5% | 55,246 | 0.0% | 0.01% | -26.3% |
| Q2 2016 | $251,000 | +34.2% | 55,246 | +3.1% | 0.02% | +18.8% |
| Q1 2016 | $187,000 | -51.9% | 53,596 | 0.0% | 0.02% | -50.0% |
| Q4 2015 | $389,000 | -55.8% | 53,596 | -20.4% | 0.03% | -60.5% |
| Q3 2015 | $880,000 | -23.2% | 67,346 | -0.3% | 0.08% | -21.4% |
| Q2 2015 | $1,146,000 | -30.2% | 67,546 | +0.1% | 0.10% | -29.5% |
| Q1 2015 | $1,641,000 | -99.9% | 67,500 | +4.7% | 0.15% | +69.8% |
| Q4 2014 | $1,215,180,000 | +146838.3% | 64,500 | +7.5% | 0.09% | +36.5% |
| Q3 2014 | $827,000 | -28.9% | 60,000 | +95.8% | 0.06% | -44.2% |
| Q3 2013 | $1,163,000 | – | 30,650 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
| TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
| Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
| Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
| Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
| Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
| Overbrook Management Corp | 48,611 | $22,000 | 0.00% |